EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 92 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.64 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $122 | -56.7% | 400 | 0.0% | 0.00% | – |
| Q2 2023 | $282 | -21.4% | 400 | 0.0% | 0.00% | – |
| Q1 2023 | $359 | -23.9% | 400 | 0.0% | 0.00% | – |
| Q4 2022 | $472 | -84.3% | 400 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q1 2022 | $3,000 | +50.0% | 400 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | -33.3% | 400 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2021 | $3,000 | -99.9% | 400 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $3,540,000 | +70700.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $5,000 | +66.7% | 400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $3,000 | -25.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $4,000 | +33.3% | 400 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $3,000 | -75.0% | 400 | -50.0% | 0.00% | -50.0% |
| Q4 2019 | $12,000 | +140.0% | 800 | +68.1% | 0.00% | 0.0% |
| Q3 2019 | $5,000 | – | 476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,787,091 | $20,462,000 | 6.02% |
| INTERWEST VENTURE MANAGEMENT CO | 1,599,592 | $18,315,000 | 3.89% |
| NEXTHERA CAPITAL LP | 263,600 | $3,018,000 | 1.54% |
| SPHERA FUNDS MANAGEMENT LTD. | 385,301 | $4,412,000 | 0.86% |
| RA Capital Management | 354,200 | $4,056,000 | 0.50% |
| DAFNA Capital Management LLC | 35,977 | $412,000 | 0.35% |
| Boxer Capital, LLC | 138,331 | $1,584,000 | 0.35% |
| SABBY MANAGEMENT, LLC | 238,907 | $2,735,000 | 0.15% |
| Monashee Investment Management LLC | 31,500 | $361,000 | 0.14% |
| Lombard Odier Asset Management (USA) Corp | 100,000 | $1,145,000 | 0.11% |